Taylor Wessing's areas of expertise include cross-border litigation, technology transfers, and innovation strategies, with strength in the pharmaceuticals, life sciences, technology, electronics, energy, and transportation segments. Frequently coordinating pan-European disputes and advising on regulatory issues, the team is led by Jules Fabre, who joined from Pinsent Masons LLP in May 2025 and focuses on high-stakes patent and SPC litigation for generics and biosimilars. Marina Jonon also joined from Pinsent Masons LLP in May 2025 and handles life sciences disputes. Clémence de Marassé-Enouf joined from A&O Shearman in June 2025, bolstering the firm's offering regarding enforcement in the pharmaceuticals and technology sectors.
Legal 500 Editorial commentary
Accolades
Client satisfaction: NPS ®
Testimonials
Collated independently by Legal 500 research team.
- ‘Highly adept patent litigation team who routinely and successfully handles highly complex patent litigation projects. They are highly knowledgable, strategic thinkers and a pleasure to work with.’
- ‘Jules Fabre is a great leader and an exceptional lawyer. He has the ability to rapidly grasp highly complex aspects of patent disputes and effectively manage his team. He is also a valued and productive member of larger teams working on multi-jurisdictional projects. Would highly recommend.’
Key clients
- Formycon
- Global Wheel
- Accord Healthcare
- Zentiva
- Georg Martin
- Precitec
- Asentys
- Griesson de Beukelaer
- Aldes
- Klinge
- Fresenius Kabi
- Rodenstock
Work highlights
Representing Accord Healthcare in a pan-European mandate to support market access and coordinating litigation for a biosimilar of Roche’s blockbuster monoclonal antibody.
Representing Accord in patent litigation against Sanofi in connection with Accord’s generic version of Sanofi’s blockbuster prostate cancer treatment, including proceedings before the UPC Munich Local Division and parallel actions in France, where the team successfully defended a fast-track preliminary injunction application before the Paris Court of First Instance.
Representing and successfully defending Zentiva in the context of an application for a fast-track preliminary injunction from Bayer against the contemplated launch of Zentiva’s generic rivaroxaban (Xarelto) product in France.
Lawyers
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
Jules Fabre
Other key lawyers
Marina Jonon; Clémence de Marassé-Enouf